Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo

Annals of Surgical Oncology

Volumn 17, Issue 1, 2010, Pages 296-303

  Cohen, Mark S ^a   Al Kasspooles, Mazin F ^a   Williamson, Stephen K ^a   Henry, David ^b   Broward, Melinda ^b   Roby, Katherine F ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PANITUMUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CARCINOMA CELL; CARCINOMATOSIS; COLORECTAL CANCER; COLORECTAL CARCINOMATOSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; SURVIVAL TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INJECTIONS, INTRAPERITONEAL; LEUCOVORIN; MICE; MICE, NUDE; MITOMYCIN; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 74649083342     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0669-0     Document Type: Article

References (69)

1. A Jemal R Siegel E Ward, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010 18287387
2. B Levin D Brooks RA Smith A Stone 2003 Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers CA Cancer J Clin 53 44 55 10.3322/canjclin.53.1.44 12568443
3. J Esquivel D Elias D Baratti, et al. 2008 Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination J Surg Oncol 98 263 267 10.1002/jso.21053 18726889
4. HI Hurwitz L Fehrenbacher JD Hainsworth, et al. 2005 Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J Clin Oncol 23 3502 3508 10.1200/JCO.2005.10.017 1:CAS:528:DC%2BD2MXlsVyhsrs%3D 15908660 (Pubitemid 46243494)
5. DZ Chu NP Lang C Thompson, et al. 1989 Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors Cancer 63 364 367 10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V 1:STN:280:DyaL1M%2FovFGnsQ%3D%3D 2910444 (Pubitemid 19035034)
6. DG Jayne S Fook C Loi F Seow-Choen 2002 Peritoneal carcinomatosis from colorectal cancer Br J Surg 89 1545 1550 10.1046/j.1365-2168.2002.02274.x 1:STN:280:DC%2BD38noslajtA%3D%3D 12445064 (Pubitemid 35404323)
7. B Sadeghi C Arvieux O Glehen, et al. 2000 Peritoneal Carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 Multicentric Prospective Study Cancer 88 358 363 10.1002/(SICI)1097-0142(20000115)88:2<358::AID- CNCR16>3.0.CO;2-O 1:STN:280:DC%2BD3c7gvVOntg%3D%3D 10640968 (Pubitemid 30051820)
8. WJ Cunliffe PH Sugarbaker 1989 Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy Br J Surg 76 1082 1090 10.1002/bjs.1800761030 1:STN:280:DyaK3c%2FovF2hsA%3D%3D 2688796
9. E Akaishi F Teixeira M Katayama, et al. 2009 Peritonectomy for peritoneal carcinomatosis: long-term outcomes from a single Brazilian institution World J Surg 33 835 839 10.1007/s00268-008-9880-6 19169741
10. WP Ceelen M Peeters P Houtmeyers, et al. 2008 Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis Ann Surg Oncol 15 535 541 10.1245/s10434-007-9648-5 17960463 (Pubitemid 351643030)
11. O Glehen F Kwiatkowski PH Sugarbaker, et al. 2004 Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study J Clin Oncol 22 3284 3292 10.1200/JCO.2004.10.012 1:STN:280:DC%2BD2cvgs1Giuw%3D%3D 15310771 (Pubitemid 41103684)
12. BL van Leeuwen W Graf L Pahlman H Mahteme 2008 Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis Ann Surg Oncol 15 745 753 10.1245/s10434-007-9700-5 18057988
13. VJ Verwaal S Bruin H Boot, et al. 2008 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer Ann Surg Oncol 15 2426 2432 10.1245/s10434-008-9966-2 18521686
14. XJ Yang Y Li AH Al-shammaa Hassan, et al. 2009 Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases Ann Surg Oncol 16 345 351 10.1245/s10434-008-0226-2 19018599
15. F Cavaliere M Valle M De Simone, et al. 2006 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a SITILO multicentric study In Vivo 20 747 750 1:CAS:528:DC%2BD2sXitleqs7Y%3D 17203760
16. TD Yan L Welch D Black PH Sugarbaker 2007 A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma Ann Oncol 18 827 834 10.1093/annonc/mdl428 1:STN:280:DC%2BD2s3ns1eqsg%3D%3D 17130182 (Pubitemid 47054078)
17. D Elias B Raynard F Farkhondeh, et al. 2006 Peritoneal carcinomatosis of colorectal origin Gastroenterol Clin Biol 30 1200 1204 1:CAS:528: DC%2BD28XhtlCnur3P 17075479
18. S Kusamura E Dominique D Baratti, et al. 2008 Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy J Surg Oncol 98 247 252 10.1002/jso.21051 18726886
19. PH Sugarbaker 2008 Building on a consensus J Surg Oncol 98 4 215 216 10.1002/jso.21078 18726906
20. D Elias T Matsuhisa L Sideris, et al. 2004 Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance Ann Oncol 15 1558 1565 10.1093/annonc/mdh398 1:STN:280:DC%2BD2cvlvVKjug%3D%3D 15367418 (Pubitemid 39409748)
21. SK Green MC Karlsson JV Ravetch RS Kerbel 2002 Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer Cancer Res 62 6891 6900 1:CAS:528:DC%2BD38XpsVahsL4%3D 12460904
22. JW Pearson DJ FitzGerald MC Willingham, et al. 1989 Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice Cancer Res 49 3562 3567 1:CAS:528:DyaL1MXkslSntLo%3D 2499420
23. O Wildner JC Morris 2000 Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses J Gene Med 2 353 360 10.1002/1521- 2254(200009/10)2:5<353::AID-JGM130>3.0.CO;2-G 1:STN:280: DC%2BD3crgtVSmsw%3D%3D 11045429
24. DC Birle DW Hedley 2006 Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts Mol Cancer Ther 5 2494 2502 10.1158/1535-7163.MCT-05-0504 1:CAS:528:DC%2BD28XhtVOmtbfO 17041093 (Pubitemid 44650913)
25. JCJ Cusack R Liu L Xia, et al. 2006 NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model Clin Cancer Res 12 6758 6764 10.1158/1078-0432.CCR-06-1151 1:CAS:528:DC%2BD28Xht1elsLzO 17121896 (Pubitemid 44876845)
26. KA Foon XD Yang LM Weiner, et al. 2004 Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody Int J Radiat Oncol Biol Phys 58 984 990 1:CAS:528:DC%2BD2cXhtVygsr4%3D 14967460
27. M Kimura T Konno Y Miyamoto, et al. 1998 Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses Anticancer Res 18 2547 2550 1:CAS:528:DyaK1cXlsF2hsro%3D 9703908
28. HH Ruan KR Scott E Bautista WS Ammons 2003 ING-1(heMAb), a monoclonal antibody to epithelial cell adhesion molecule, inhibits tumor metastases in a murine cancer model Neoplasia 5 489 494 1:CAS:528:DC%2BD2cXht1Wgtro%3D 14965442
29. KF Roby CC Taylor JP Sweetwood, et al. 2000 Development of a syngeniec mouse model for events related to ovarian cancer Carcinogenesis 21 585 591 10.1093/carcin/21.4.585 1:CAS:528:DC%2BD3cXivFKktL8%3D 10753190
30. LB Saltz JV Cox C Blanke, et al. 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 905 914 10.1056/NEJM200009283431302 1:CAS:528:DC%2BD3cXntFOkt7Y%3D 11006366 (Pubitemid 30727802)
31. F Caponigro A Milano A Ottaiano RV Iaffaioli 2006 Epidermal growth factor receptor as a major anticancer drug target Expert Opin Ther Targets 10 877 888 10.1517/14728222.10.6.877 1:CAS:528:DC%2BD28Xht1Smt7zK 17105374 (Pubitemid 44816750)
32. JB Johnston S Navaratnam MW Pitz, et al. 2006 Targeting the EGFR pathway for cancer therapy Curr Med Chem 13 3483 3492 10.2174/092986706779026174 1:CAS:528:DC%2BD28Xht1aks7fF 17168718 (Pubitemid 44873742)
33. J Nautiyal AK Rishi AP Majumdar 2006 Emerging therapies in gastrointestinal cancers World J Gastroenterol 12 7440 7450 1:CAS:528: DC%2BD2sXhtFyrsL4%3D 17167831
34. M Scaltriti J Baselga 2006 The epidermal growth factor receptor pathway: a model for targeted therapy Clin Cancer Res 12 5268 5272 10.1158/1078-0432.CCR- 05-1554 1:CAS:528:DC%2BD28XpvFShs74%3D 17000658 (Pubitemid 44497237)
35. RG Amado M Wolf M Peeters, et al. 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626 1634 10.1200/JCO.2007.14.7116 1:CAS:528:DC%2BD1cXltlWhsrw%3D 18316791
36. M Jhawer S Goel A Wilson, et al. 2008 PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab Cancer Res 68 1953 1961 10.1158/0008-5472.CAN-07- 5659 1:CAS:528:DC%2BD1cXjtFOhtro%3D 18339877
37. A de Gramont A Figer M Seymour, et al. 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938 2947 10944126
38. JA Meyerhardt RJ Mayer 2005 Systemic therapy for colorectal cancer N Engl J Med 352 476 487 10.1056/NEJMra040958 1:CAS:528:DC%2BD2MXptlWkuw%3D%3D 15689586 (Pubitemid 40175974)
39. D Elias JH Lefevre J Chevalier, et al. 2009 Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin J Clin Oncol 27 681 685 10.1200/JCO.2008.19. 7160 19103728
40. D Balin-Gauthier JP Delord P Rochaix, et al. 2006 In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR Cancer Chemother Pharmacol 57 709 718 10.1007/s00280-005-0123-3 1:CAS:528:DC%2BD28XjtlWns7w%3D 16320055
41. TW Bauer F Fan W Liu, et al. 2007 Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice Ann Surg Oncol 14 2838 2846 17653802
42. C Leonetti M Scarsella G Zupi, et al. 2006 Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts Mol Cancer Ther 5 919 926 10.1158/1535-7163.MCT-05-0536 1:CAS:528:DC%2BD28XjvFCktrg%3D 16648562 (Pubitemid 43724591)
43. C Moser SA Lang S Kainz, et al. 2007 Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo Mol Cancer Ther 6 2868 2878 10.1158/1535-7163.MCT-07-0410 1:CAS:528:DC%2BD2sXhtlWkt7nK 18025273 (Pubitemid 350206765)
44. J Tabernero E Van Cutsem E Díaz-Rubio, et al. 2007 Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Clin Oncol 25 5225 5232 10.1200/JCO.2007.13.2183 1:CAS:528:DC%2BD2sXhsVKnsbzI 18024868 (Pubitemid 350232254)
45. IA Vasilevskaya M Selvakumaran P O'Dwyer 2008 Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin Mol Pharmacol 74 246 254 10.1124/mol.107.044644 1:CAS:528:DC%2BD1cXot1aktro%3D 18436711 (Pubitemid 351872175)
46. Y Yao H Zhao Y Sun, et al. 2008 Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer Tohoku J Exp Med 215 267 278 10.1620/tjem.215.267 1:CAS:528:DC%2BD1cXhtVSgsLjO 18648187
47. A Hribaschek M Pross R Kuhn, et al. 2002 Prevention and treatment of peritoneal carcinomatosis in experimental investigations with CPT-11 and oxaliplatin Anticancer Drugs 13 605 614 10.1097/00001813-200207000-00007 1:CAS:528:DC%2BD38Xmt12isLg%3D 12172506 (Pubitemid 34816455)
48. S Yokoo S Masuda A Yonezawa, et al. 2008 Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer Drug Metab Dispos 36 2299 2306 10.1124/dmd.108.023168 1:CAS:528:DC%2BD1cXhtlWiu77O 18710896
49. ZH Huang D Hua X Du, et al. 2008 ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer World J Gastroenterol 14 6401 6407 10.3748/wjg.14.6401 1:CAS:528: DC%2BD1MXis1eltbY%3D 19009659
50. SH Kim HC Kwon SY Oh, et al. 2009 Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer Am J Clin Oncol 32 38 43 1:CAS:528: DC%2BD1MXhtlGktbs%3D 19194123
51. I Fichtner W Slisow J Gill, et al. 2004 Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas Eur J Cancer 40 298 307 10.1016/j.ejca.2003.10.011 1:CAS:528:DC%2BD2cXjsVOltQ%3D%3D 14728946 (Pubitemid 38077034)
52. F Mohamed P Marchettini OA Stuart, et al. 2003 Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia Ann Surg Oncol 10 463 468 10.1245/ASO.2003.08.006 12734097 (Pubitemid 40486946)
53. SR Pestieau JF Belliveau H Griffin, et al. 2001 Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies J Surg Oncol 76 106 114 10.1002/1096-9098(200102)76:2<106::AID-JSO1020>3.0.CO;2-E 1:CAS:528:DC%2BD3MXhsFahsLg%3D 11223836 (Pubitemid 32164637)
54. F Aarts T Hendriks OC Boerman, et al. 2007 A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats Ann Surg Oncol 14 3274 3282 10.1245/s10434-007-9509-2 1:STN:280:DC%2BD2snht1GmtA%3D%3D 17653591 (Pubitemid 47594277)
55. JO Pelz J Doerfer W Hohenberger T Meyer 2005 A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis BMC Cancer 5 56 10.1186/1471-2407-5-56 15924622 (Pubitemid 41461074)
56. S Le Page F Kwiatkowski C Paulin, et al. 2006 In vitro thermochemotherapy of colon cancer cell lines with irinotecan alone and combined with mitomycin C Hepatogastroenterology 53 693 697 1:CAS:528:DC%2BD28Xht1eqs7vP 17086870
57. K Van der Speeten OA Stuart PH Sugarbaker 2009 Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy Curr Drug Discov Technol 6 72 81 10.2174/157016309787581084 19275544
58. DK Armstrong B Bundy L Wenzel, et al. 2006 Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 34 43 10.1056/NEJMoa052985 1:CAS:528:DC%2BD28XhvV2qsQ%3D%3D 16394300 (Pubitemid 43048949)
59. F Giuliani S Molica E Maiello, et al. 2005 Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106) Am J Clin Oncol 28 581 585 10.1097/01.coc.0000190398.52142.7f 1:CAS:528: DC%2BD28Xit12jsA%3D%3D 16317268 (Pubitemid 41790010)
60. K Nishino Y Aoki T Amikura, et al. 2005 Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma Gynecol Oncol 97 893 897 10.1016/j.ygyno.2005.03.009 1:CAS:528:DC%2BD2MXltFSgsrk%3D 15894369 (Pubitemid 40824662)
61. Y Yamada K Shirao I Hyodo, et al. 2003 Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer Cancer Chemother Pharmacol 52 125 130 10.1007/s00280-003-0604-1 1:CAS:528:DC%2BD3sXlsVylsb8%3D 12783200 (Pubitemid 37041345)
62. T Kuzuya M Yamauchi A Ito, et al. 1994 Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy J Pharm Pharmacol 46 685 689 1:CAS:528:DyaK2cXls12ltbo%3D 7815285
63. PH Sugarbaker T Graves EA DeBruijn, et al. 1990 Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies Cancer Res 50 5790 5794 1:STN:280:DyaK3czmslSjtA%3D%3D 2118420
64. PH Sugarbaker OA Stuart J Vidal-Jove, et al. 1996 Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration Cancer Treat Res 82 41 1:STN:280:DyaK2s%2Fgt1Gqtw%3D%3D 8849942
65. D Elias B Raynard M Bonnay M Pocard 2006 Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studies Eur J Surg Oncol 32 607 613 10.1016/j.ejso.2006.03.004 1:STN:280:DC%2BD28vjs12ktQ%3D%3D 16621432 (Pubitemid 44063994)
66. A Hribaschek R Kuhn M Pross, et al. 2006 Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model Surg Today 36 57 62 10.1007/s00595-004-3096-7 1:CAS:528:DC%2BD2MXhtlGhsLvL 16378195 (Pubitemid 43015856)
67. C Gobert L Bracco F Rossi, et al. 1996 Modulation of DNA topoisomerase I activity by p53 Biochemistry 35 5778 5786 10.1021/bi952327w 1:CAS:528: DyaK28XitlWqsbo%3D 8639538 (Pubitemid 26143674)
68. MA Villalona-Calero JM Kolesar 2002 Mitomycin as a modulator of irinotecan anticancer activity Oncology 16 21 25 12199629
69. Y Xu CL Shapiro 2003 Rationale for mitomycin and irinotecan use in advanced breast cancer Oncology 17 25 28 1:CAS:528:DC%2BD3sXhvFGgtbw%3D 12800602